PLUS1
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Madrigal Pharmaceuticals Inc | MDGL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -3.16 | -3.04% | 100.65 | 103.34 | 100.00 | 102.88 | 103.81 | 11:20:47 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 100.67 | 101.11 | 0.44 | 0.44% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 573 | 39,982 | $ 101.64 | $ 4,063,862 | 127,413 | 82.31 - 153.60 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:19:17 | 19 | $ 100.95 | USD |
Madrigal Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 1.56B | 15.43M | $ -32.81M | -2.22 | - | 6.71M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Madrigal Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/11/2019 | 17:30 | GlobeNewswire Inc. | Madrigal Pharmaceuticals Announces Publication in The Lancet.. |
| 11/06/2019 | 08:32 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/06/2019 | 06:50 | GlobeNewswire Inc. | Madrigal Pharmaceuticals Reports 2019 Third Quarter.. |
| 11/06/2019 | 06:07 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 10/17/2019 | 15:47 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
| 10/17/2019 | 15:46 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
| 10/17/2019 | 15:45 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MDGL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 92.83 | 109.035 | 91.54 | 102.67 | 141,980 | 7.82 | 8.42% |
| 1 Month | 87.45 | 109.035 | 85.3234 | 95.56 | 121,582 | 13.20 | 15.09% |
| 3 Months | 94.43 | 109.035 | 82.31 | 93.87 | 173,960 | 6.22 | 6.59% |
| 6 Months | 100.52 | 109.035 | 82.31 | 94.94 | 167,410 | 0.13 | 0.13% |
| 1 Year | 150.77 | 153.60 | 82.31 | 110.05 | 209,379 | -50.12 | -33.24% |
| 3 Years | 16.50 | 325.98 | 13.0886 | 143.02 | 172,801 | 84.15 | 510.0% |
| 5 Years | 8.35 | 325.98 | 6.60 | 140.79 | 159,148 | 92.30 | 1,105.39% |
Madrigal Pharmaceuticals Description
| Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed ß-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. In addition, MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |
